Conventional treatment
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 97 | 潰瘍性大腸炎 | 5 |
97. 潰瘍性大腸炎
臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
Showing 1 to 5 of 5 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05610956 (ClinicalTrials.gov) | December 1, 202220221201 | 31/10/202220221031 | Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis | Clinical Study to Evaluate the Possible Efficacy and Safety of Empagliflozin in Patients With Ulcerative Colitis Clinical Study to Evaluate the Possible Efficacy and Safety of Empagliflozin in Patients With Ulcera ... | Ulcerative Colitis | Drug: Empagliflozin;Drug: conventional treatment | Tanta University | NULL | Not yet recruiting | 18 Years | 70 Years | All | 60 | Early Phase 1 | NULL |
| 2 | NCT05386290 (ClinicalTrials.gov) | July 9, 202020200709 | 17/5/202220220517 | A Multicentered Prospective Cohort Study of Chinese IBD Patients | A Multicentered Prospective Cohort Study of Chinese IBD Patients Concerning Cost-effectiveness Analysis, Therapeutic Effect Predictor Exploration and Gut Microbiota Analysis A Multicentered Prospective Cohort Study of Chinese IBD Patients Concerning Cost-effectiveness Analy ... | Ulcerative Colitis;Crohn Disease | Drug: Infliximab;Drug: Vedolizumab;Drug: Ustekinumab;Drug: conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine) Drug: Infliximab;Drug: Vedolizumab;Drug: Ustekinumab;Drug: conventional treatment(glucocoticoid, imm ... | Peking Union Medical College Hospital | NULL | Enrolling by invitation | 14 Years | 80 Years | All | 200 | China | |
| 3 | NCT03609905 (ClinicalTrials.gov) | July 1, 201820180701 | 1/6/201820180601 | Adipose Mesenchymal Stem Cells (AMSC) for Treatment of Ulcerative Colitis | A Phase I/II Randomized, Controlled, Clinical Trial for Assessment of the Safety and Efficacy of Allogeneic Adipose Mesenchymal Stem Cells in Moderate to Severe Ulcerative Colitis Patients A Phase I/II Randomized, Controlled, Clinical Trial for Assessment of the Safety and Efficacy of All ... | Ulcerative Colitis (UC) | Biological: Adipose-cord mesenchymal stromal cells (A-MSCs);Other: Conventional drugs | Liaocheng People's Hospital | NULL | Recruiting | 18 Years | 65 Years | All | 50 | Phase 1/Phase 2 | China |
| 4 | EUCTR2012-004768-23-DE (EUCTR) | 12/06/201320130612 | 06/02/201320130206 | A Phase 2a Trial of STNM01 by a Single Submucosal Injection to Investigate the Mucosal Healing Efficacy in Patients with Ulcerative Colitis A Phase 2a Trial of STNM01 by a Single Submucosal Injection to Investigate the Mucosal Healing Effic ... | A Phase 2a Trial of STNM01 by a Single Submucosal Injection to Investigate the Mucosal Healing Efficacy in Patients with Ulcerative Colitis A Phase 2a Trial of STNM01 by a Single Submucosal Injection to Investigate the Mucosal Healing Effic ... | Ulcerative Colitis with active endoscopic lesion(s), ranging in severity from moderate to severe in endoscopic score not responding sufficiently to conventional treatment MedDRA version: 19.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Ulcerative Colitis with active endoscopic lesion(s), ranging in severity from moderate to severe in ... | Product Name: STNM01 1.84 mg Product Code: STNM01 INN or Proposed INN: STNM01 | STELIC INSTITUTE & CO. | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | Germany | |||
| 5 | EUCTR2009-013890-16-PT (EUCTR) | 28/05/201020100528 | 21/12/200920091221 | Herica - Histological and Endoscopic evaluation of Remission induced by Infliximab in moderately to severely active ulcerative Colitis Patients - Herica Herica - Histological and Endoscopic evaluation of Remission induced by Infliximab in moderately to ... | Herica - Histological and Endoscopic evaluation of Remission induced by Infliximab in moderately to severely active ulcerative Colitis Patients - Herica Herica - Histological and Endoscopic evaluation of Remission induced by Infliximab in moderately to ... | This national, multi-centre, open-label pilot study will assess the histologic remission in patients with moderate to severe active ulcerative colitis under infliximab treatment who have had an inadequate response to conventional therapy.Biopsies will be analyzed throughout the study in order to assess histological disease modifying effects in those patients. MedDRA version: 16.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856 This national, multi-centre, open-label pilot study will assess the histologic remission in patients ... | Trade Name: Remicade Product Name: Remicade | GEDII - Grupo de Estudo da Doença inflamatória Intestinal | NULL | Not Recruiting | Female: yes Male: yes | 20 | Portugal |